Ibrutinib (Imbruvica) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * Français SearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs and health
Ibrutinib (Imbruvica) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * Français SearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs and health
Ibrutinib (previously untreated chronic lymphocytic leukaemia) ' Addendum to Commission A23-04 1 Translation of addendum A23-54 Ibrutinib (nicht vorbehandelte chronische lymphatische Leukämie) – Addendum zum Projekt A23-04 (Dossierbewertung). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Ibrutinib (previously untreated chronic lymphocytic leukaemia) Addendum to Project A23-04 (dossier assessment)1 ADDENDUM Project: A23-54 Version: 1.0 Status: 29 June 2023 Addendum A23-54 Version 1.0 Ibrutinib – Addendum to Project A23-04 29 June 2023 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing
Ibrutinib (chronic lymphocytic leukaemia, first line) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Ibrutinib (nicht vorbehandelte chronische lymphatische Leukämie) – Nutzenbewertung gemäß § 35a SGB V. Please note: This document was translated by an external translator and is provided as a service by IQWiG to English -language readers. However, solely the German original text is absolutely authoritative and legally binding. Ibrutinib (previously untreated chronic lymphocytic leukaemia) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-04 Version: 1.0 Status: 24 April 2023 Extract of dossier assessment A23-04 Version 1.0 Ibrutinib (previously untreated chronic lymphocytic leukaemia) 24 April 2023
Ibrutinib: increased risk of sudden death Register online | Log in | My PrescrireISSUE CONTENTSTOPICSABOUT PRESCRIREOFFERSenglish.prescrire.org > Spotlight > 100 most recent > Ibrutinib: increased risk of sudden deathSpotlightEvery month, the subjects in Prescrire’s Spotlight.100 most recent : 1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90Spotlight100 most recentArchivesIbrutinib: increased risk of sudden death Adverse Effects Data from clinical trials show a 5-fold greater risk of sudden or cardiac death with ibrutinib than with comparators.In late 2022, the company which markets ibrutinib reported that "assessment of data from the randomised clinical trials pool of ibrutinib" showed that the crude incidence of sudden or cardiac death was approximately 5 times higher in patients taking
Ibrutinib (Imbruvica) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review and approval 6. Clinical information on drugs
Ibrutinib (Imbruvica) - Waldenstr'm's macroglobulinemia View of Ibrutinib (Imbruvica) | Canadian Journal of Health TechnologiesReturn to Article DetailsIbrutinib (Imbruvica)
Ibrutinib (Imbruvica) - Waldenstrom macroglobulinemia View of Ibrutinib (Imbruvica) | Canadian Journal of Health TechnologiesReturn to Article DetailsIbrutinib (Imbruvica)
Ibrutinib (Imbruvica) - chronic lymphocytic leukaemia (CLL) Published 11 September 2023 1 SMC2543 ibrutinib film-coated tablets (Imbruvica®) Janssen-Cilag Ltd. 04 August 2023 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the orphan equivalent medicine process ibrutinib (Imbruvica®) is accepted for use within NHSScotland. Indication under review: in combination with venetoclax for the treatment of adult patients
Ibrutinib (CLL) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Ibrutinib (chronische lymphatische Leukämie) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 23 December 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A20-88 Ibrutinib (chronic lymphocytic leukaemia) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A20-88 Version 1.0 Ibrutinib (chronic lymphocytic leukaemia) 23 December 2020 Institute for Quality and Efficiency in Health Care
Ibrutinib (Imbruvica) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL) Rothschedl, E. and Wolf, S.(2022):Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL). Oncology Fact
Ibrutinib (Imbruvica) - chronic lymphocytic leukaemia Published 11 April 2022 4 March 2022 ADVICE: in the absence of a submission from the holder of the marketing authorisation ibrutinib (Imbruvica®) is not recommended for use within NHSScotland. Indication under review: In combination with rituximab for the treatment of adult patients with previously untreated chronic lymphocytic in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. Chairman Scottish Medicines Consortium Statement of advice SMC2485 ibrutinib 140mg, 280mg, 420mg and 560mg film- coated tablets (Imbruvica®) Janssen-Cilag Ltd www.scottishmedicines.org.uk
Ibrutinib for Chronic Graft versus Host Disease Skip to main contentAboutCollaboration/OutreachPatient/CommunityCareersContactMy CADTHFRReportsResourcesProvide InputSubmit a RequestNews & EventsWhat Does The Evidence Say About...SearchBreadcrumbHome Ibrutinib for Chronic Graft versus Host DiseaseCopied to clipboardIbrutinib for Chronic Graft versus Host Disease( Last Updated : June 24, 2022 )Project Line:Health Technology ReviewProject Sub Line:Summary with Critical AppraisalProject Number:RC1433-000DetailsQuestionWhat is the clinical effectiveness of ibrutinib in patients with chronic graft-versus-host disease who have inadequate response to corticosteroids or other systemic therapies?Key MessageNo eligible evidence was identified comparing ibrutinib to another intervention
Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma ACE Technology Guidances A Singapore Government Agency Website SEARCH Who We Are Organisational Structure Our Council and Expert Panels Committees We Serve Careers at ACE Healthcare Professionals ACE Clinical Guidances (ACGs) ACE CUES ACE Technology Guidances ACE Horizon Scanning Patients & Community Asthma Resources Plain Updated on 12 Jul 2022 A- A+ Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma (12 Jul 22) Acalabrutinib, bortezomib and ibrutinib for treating mantle cell lymphoma PES (12 Jul 22) 21 Feb 2022Agency for Care Effectiveness (ACE)Who We Are * Organisational Structure * Our Council and Expert Panels * Committees We Serve * Careers at ACE Healthcare Professionals * ACE Clinical